|
| |
|
| 8.30 – 8.40 a.m. |
Opening by Heinz Zwierzina and Reiner Gradinger
|
8.40 - 10.20 a.m.
8.40 - 9.05 a.m.
9.05 - 9.30 a.m.
9.30 - 9.55 a.m.
9.55 - 10.20 a.m. |
Improving Immune-mediated Cancer Control
Chair: L. Hakansson, S. Hirschfeld
Relevant immune parameters in monitoring cancer
immunotherapy – an overview
C. Melief, Leiden
Challenges and potential solutions in biomarker
development
S. Hirschfeld, Bethesda
Immune profi ling of glioblastoma cancer stem cells
G. Parmiani, Milan
Adoptive transfer of NK cells combined with radiotherapy –
a new concept in the treatment of NSCLC
G. Multhoff, Munich
|
| 10.20 – 11.00 a.m. |
Coffee Break |
11.00– 12:30 a.m.
|
Immmunosuppressor Mechanisms
Chair: G. Parmiani, W. Hiddemann |
11.00 - 11.30 a.m.
11.30 - 12.00 a.m.
12.00 - 12.10 a.m.
12.10 - 12.20 a.m.
12.20 - 12.30 a.m. |
Induction, regulation and function of regulatory T-cells in
cancer
G. Betts, Cardiff
Myeloid suppressor cells and their role in the development of
specifi c T-cell responses to melanoma vaccines
L. Rivoltini, Milan
Free communications
Combination chemotherapy prior to reconstitution with autologous
PBMC and vaccination with autologous tumor and
GM-CSF fails to induce long-term reduction of FoxP3+ cells
in NSCLC patients
N. Van den Engel, Munich
A clinical and immunological phase II trial of Wilms Tumor
Gene Product 1 (WT1) peptide vaccination in patients with
AML and MDS
A. Letsch, Berlin
Kinetic of initiation of an in vivo cytolytic response of
NK Cells
against HSP70-positive tumor
V. Milani, Munich |
| 12.30 – 1.30 p.m. |
Lunch |
| 1.30– 4.00 p.m. |
Joint BDA and iSBTc Workshop: Improving the
therapeutic efficacy of cancer immunotherapy
Chair: J. Wiggington, H. Zwierzina |
1.30 - 2.00 p.m.
2.00 - 2.30 p.m.
2.30 - 3.00 p.m.
3.00 – 3.30 p.m.
3.30 – 4.00 p.m. |
Combining different modalities in immunotherapy of cancer
J. Wiggington, North Wales, USA
How can the effect of therapeutic cancer vaccines be
enhanced?
A. Dalgleish, London
Can immunostimulation over-come cancer related
immunosuppression?
S. Khleif, Bethesda
Enhancing the immune mediated anti-cancer reactivity by
co-stimulation
J. Gulley, Bethesda
The missing link – cancer generated immunosuppression
L. Håkansson, Linköping |
| 4.00 – 4.30 p.m. |
Coffee Break |
| 4.30 – 6.45 p.m. |
Clinical Case Stories
Chair: S. Khleif, A.S. Shimosaka |
4.30 - 4.50 p.m.
4.50 – 5.10 p.m.
5.10 – 5.30 p.m.
5.30 – 5.50 p.m.
5.50 – 6.00 p.m.
|
Clinical development of ONYVAX-SGCRO01
C. Beattie, London
Immunomodulatory drugs (IMiDs®):
Development, biological effects and clinical applications
A. Glasmacher, Munich
A glycoengineered anti-CD19 antibody with enhanced ADCC
effector function for the treatment of B-cell malignancies
B. Jallal, Gaithersburg
Therapeutic window of a single-chain antibody construct
bispecifi c for EpCAM and CD3 – a biosimilar approach
P. A. Baeuerle, Munich
Free communication
The SpheroPCT Study: The Spheroid Microtumor Model is predictive
for the therapeutic response of colorectal cancers
M. Joka, Munich |
| |
Round table discussion |